Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin

Journal of Hypertension

Volumn 30, Issue 1, 2012, Pages 107-116

  Kühnast, Susan ^a,b   Van Der Hoorn, José W A ^a,b   Van Den Hoek, Anita M ^a,b   Havekes, Louis M ^a,b   Liau, Gene ^c   Jukema, J Wouter ^b   Princen, Hans M G ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

aliskiren; APOE*3Leiden.CETP mice; atherosclerosis; atorvastatin; hypertension; plaque stability

Indexed keywords

ALISKIREN; APOLIPOPROTEIN E3; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 83455178367     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834ddd8e     Document Type: Article

References (44)

1. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74:213-220.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
3. Libby P, Sasiela W. Plaque stabilization: can we turn theory into evidence? Am J Cardiol 2006; 98 (11A):26-33.
4. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27:165-197.
5. Jankowski P, Bilo G, Kawecka-Jaszcz K. The pulsatile component of blood pressure: its role in the pathogenesis of atherosclerosis. Blood Press 2007; 16:238-245. (Pubitemid 47542947)
6. Lu H, Cassis LA, Daugherty A. Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets 2007; 8:1181-1189. (Pubitemid 350238919)
7. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51:1306-1311. (Pubitemid 351555942)
8. Ferrario CM, Richmond RS, Smith R, Levy P, Strawn WB, Kivlighn S. Reninangiotensin system as a therapeutic target in managing atherosclerosis. Am J Ther 2004; 11:44-53.
9. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Ther Clin Risk Manag 2009; 5:459-464.
10. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004; 110:3849-3857. (Pubitemid 40023984)
11. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110:3062-3067. (Pubitemid 39491999)
12. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76:23-31.
13. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009; 2009:752406.
14. Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4:6-10. (Pubitemid 36443380)
15. Lu H, Rateri DL, Feldman DL, Charnigo RJ Jr, Fukamizu A, Ishida J, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118:984-993. (Pubitemid 351364606)
16. Grote K, Drexler H, Schieffer B. Renin-angiotensin system and atherosclerosis. Nephrol Dial Transplant 2004; 19:770-773. (Pubitemid 38455643)
17. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the reninangiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag 2007; 3:937-945.
18. Unger T, Stoppelhaar M. Rationale for double renin-angiotensinaldosterone system blockade. Am J Cardiol 2007; 100 (3A):25J-31J.
19. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7:399-410. (Pubitemid 351619112)
20. Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25:1775-1782. (Pubitemid 47364583)
21. McAlister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. Can Med Assoc J 2011; 183:655-662.
22. O'Brien E. Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin Investig Drugs 2006; 15:1269-1277. (Pubitemid 44608264)
23. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67:1767-1792. (Pubitemid 47263181)
24. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.
25. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1:17-24.
26. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. (Pubitemid 351793017)
27. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52:563-572.
28. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, et al. Cholesteryl ester transfer protein decreases highdensity lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006; 26:2552-2559. (Pubitemid 44607480)
29. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007; 48:1763-1771. (Pubitemid 47311993)
30. de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008; 117:2515-2522. (Pubitemid 351670459)
31. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008; 197:57-63. (Pubitemid 351273273)
32. van der Hoorn JW, de Haan W, Berbee JF, Havekes LM, Jukema JW, Rensen PC, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008; 28:2016-2022.
33. Zadelaar S, Kleemann R,Verschuren L, de Vries-van derWeij J, van derHoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27:1706-1721. (Pubitemid 47207165)
34. van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens 2007; 25:2454-2462. (Pubitemid 350060384)
35. Groot PH, van Vlijmen BJ, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, et al. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996; 16:926-933. (Pubitemid 26266889)
36. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, InsullWJr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15:1512-1531.
37. Delsing DJ, Offerman EH, van Duyvenvoode W, van der Boom H, de Wit EC, Gijbels MJ, et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in APOE*3-Leiden mice. Circulation 2001; 103:1778-1786. (Pubitemid 32291416)
38. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61:1835-1881. (Pubitemid 32980510)
39. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 2008; 97:418-431.
40. Bu DX, Lichtman AH. T cells and blood vessels: costimulation turns up the pressure. Circulation 2010; 122:2495-2498.
41. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460. (Pubitemid 47529329)
42. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30:1282-1292.
43. Moreno PR. The high-risk thin-cap fibroatheroma: a new kid on the block. Circ Cardiovasc Interv 2009; 2:500-502.
44. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Oie E, et al. Atherosclerotic plaque stability: what determines the fate of a plaque? Prog Cardiovasc Dis 2008; 51:183-194.